'But it got worse. The fatigue – the same fatigue I'd ironically gone to the GP for in the first place – got worse. I ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Groundbreaking weight-loss drugs like Ozempic and Wegovy do not address the problem fueling the global obesity crisis: our ...

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

Wegovy and Ozempic are weight loss drugs that promise to transform the treatment of obesity, heart disease and other chronic conditions that afflict millions of Americans. But while everyone agrees ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

As the drugs have gained name recognition among adults, they’ve also become increasingly popular with children and adolescents. But are the safe?

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...